EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Prognosis Prediction Model for Endometrial Cancer Based on DNA Methylation Signature

Ran Ran, Ming Wang iD, Jinwei Miao

Cancer Reports · 2025

DOI: 10.1002/cnr2.70218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Ran Ran und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Beijing Youan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Endometrial Neoplasms, DNA Methylation, Biomarkers, Tumor, Neoplasm Recurrence, Local. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

DNA methylation alteration is a common event during the carcinogenesis and progression of endometrial cancer (EC). Our study aimed to investigate the value of DNA methylation‐related genes in predicting the prognosis and immunotherapy response for EC patients.

Methods

The clinical information and the expression of DNA methylation‐related genes of 544 endometrial cancers were obtained from the Cancer Genome Atlas (TCGA) database. The univariate Cox regression analysis and the LASSO regression analysis were subsequently used to identify prognosis‐related methylation regulators and construct a risk model. Gene functional enrichment analysis, immune infiltration analysis, drug sensitivity analysis, and molecular feature analysis were performed in different subgroups.

Results

25 methylation‐Related gene signatures were found in EC patients and are correlated to tumor differentiation and tumor metastasis. By LASSO‐Cox regression analyses, a recurrence prediction model and a prognostic‐related model were constructed based on methylation‐related genes in the TCGA training cohort. The Area Under the Curve (AUC) values of the recurrence prediction model were 0.671, 0.708, and 0.689 for 1‐, 3‐, and 5‐year time points, respectively, while those of the prognostic model were 0.731, 0.717, and 0.725. The relationship of risk score (RS) with ER/PR‐related genes, immune checkpoint expressions, and IC50s of paclitaxel, cisplatin, tamoxifen, and cetuximab was investigated. The results showed That patients in the low‐risk group are more effective in cetuximab and immune checkpoint blockade (ICB) treatment.

Conclusions

The model based on the methylation‐related genes showed promising outcomes in predicting the recurrence and treatment response of EC. The patients with high‐risk scores showed a poorer prognosis and may benefit more from the treatment of cetuximab or immune checkpoint inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsDNA MethylationBiomarkers, TumorNeoplasm Recurrence, LocalHumansFemalePrognosisGene Expression Regulation, NeoplasticMiddle AgedImmune Checkpoint InhibitorsRisk Assessment

Stichwörter der Autor:innen

DNA methylationendometrial cancerprognosistargeted treatment

Substanzen

Biomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Obstetrics, Beijing Youan Hospital, Capital Medical University, Beijing, China.
  • Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University. Beijing Maternal and Child Health Care Hospital, Beijing, China.

ORCID-Profile: Ming Wang

Zitieren

APA

Ran, R., Wang, M., & Miao, J. (2025). The Prognosis Prediction Model for Endometrial Cancer Based on DNA Methylation Signature. Cancer Reports. https://doi.org/10.1002/cnr2.70218

Vancouver

Ran R, Wang M, Miao J. The Prognosis Prediction Model for Endometrial Cancer Based on DNA Methylation Signature. Cancer Reports. 2025. doi:10.1002/cnr2.70218

BibTeX
@article{Ran2025,
  author = {Ran, Ran and Wang, Ming and Miao, Jinwei},
  title = {The Prognosis Prediction Model for Endometrial Cancer Based on DNA Methylation Signature},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70218}
}
Kostenlos starten →